Sp188
A 64 MALE WITH NASH CIRRHOSIS AND AKI
Date
May 6, 2023
Explore related products in the following collection:
Society: AGA
This session proposed to cover common GI consults on management of patients with liver disease seen at both community and academic centers. Case based presentations on common scenarios such as elevated liver enzymes, autoimmune hepatitis, drug induced liver injury, acute kidney injury in cirrhosis, portal venous thrombosis in cirrhosis, and jaundice in a patient with alcohol-associated liver disease will outline an approach to diagnosis, discussing differential diagnosis, therapeutic options covering rationale for choosing specific options in different clinical settings. LIVE STREAM SESSION
This session proposed to cover common GI consults on management of patients with liver disease seen at both community and academic centers. Case based presentations on common scenarios such as elevated liver enzymes, autoimmune hepatitis, drug induced liver injury, acute kidney injury in cirrhosis, portal venous thrombosis in cirrhosis, and jaundice in a patient with alcohol-associated liver disease will outline an approach to diagnosis, discussing differential diagnosis, therapeutic options covering rationale for choosing specific options in different clinical settings. LIVE STREAM SESSION
Presenter
Michigan Medicine, University of Michigan
Tracks
Related Products
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
INTRODUCTION
SOCIETY: AGA
PANEL DISCUSSION
This session proposed to cover common GI consults on management of patients with liver disease seen at both community and academic centers…
